BPC-157 vs TB-500
The two most-studied repair peptides — different origins, frequently examined together.
The short answer: BPC-157 acts largely locally on angiogenesis; TB-500 acts systemically on actin dynamics.
BPC-157
TB-500
Side by side
| Property | BPC-157 | TB-500 |
|---|---|---|
| Research category | Recovery Research | Recovery Research |
| Presentation | 5mg vial | 5mg vial |
| Dosage options | 5mg · 10mg | 5mg · 10mg |
| Approved medicine using it | None — investigational | None — investigational |
| Availability | In stock | In stock |
| Batch COA | Supplied with order | Supplied with order |
| From | €89.00 | €89.00 |
How they differ
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein present in most cells and in wound fluid. They share a research area, not an origin.
Their mechanisms are studied differently. BPC-157 is most associated with angiogenesis and with upregulation of growth factor receptors at the site of injury, so much of the literature is local. TB-500 binds G-actin and influences cell migration, a mechanism that is inherently more systemic.
Because the two mechanisms are largely independent, they are commonly studied in parallel rather than as alternatives — which is why they appear at the same price point in this catalogue.
At the bench
Both arrive lyophilised and both need reconstituting, so the maths is the same for each. At these masses the draw volumes are small enough that barrel width matters more than capacity. They are commonly prepared in parallel rather than chosen between.
What this comparison does not settle
Most of the published work on both is preclinical and in animal models. This comparison describes mechanisms studied, not effects established, and the distance between those two things is wide here.
Common questions
What is the difference between BPC-157 and TB-500?
BPC-157 acts largely locally on angiogenesis; TB-500 acts systemically on actin dynamics. The two most-studied repair peptides — different origins, frequently examined together.
Is BPC-157 or TB-500 better?
Neither, and the question does not have a general answer. They are compared here on mechanism rather than merit. Most of the published work on both is preclinical and in animal models. This comparison describes mechanisms studied, not effects established, and the distance between those two things is wide here.
Which of the two has more published data?
Neither has an approved formulation — both are investigational, and the published work on each is correspondingly narrower.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. Brand names are trademarks of their respective owners and are referenced only to identify the active compound — no affiliation or equivalence is claimed.